- SynonymCoagulation factor XI,FXI,PTA,F11
- SourceHuman Coagulation factor XI, His Tag (FXI-H52H5) is expressed from human 293 cells (HEK293). It contains AA Glu 19 - Val 625 (Accession # P03951-1).Predicted N-terminus: Glu 19Request for sequence
- Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus. The proprotein is activated by factor XIIa (or XII) and cleaved after Arg-387 into the light chain with calculated MW of 28.7 kDa, which contains the active site, and the heavy chain with calculated MW of 41.2 kDa. The protein migrates as 47 kDa (heavy chain) and 35 kDa (light chain) under reducing (R) condition (SDS-PAGE) due to glycosylation.
- EndotoxinLess than 1.0 EU per μg by the LAL method.
- Purity
>90% as determined by SDS-PAGE.
- Formulation
Lyophilized from 0.22 μm filtered solution in 25 mM HEPES, 150 mM NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
- Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
- Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Human Coagulation factor XI, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
Measured by its ability to cleave the fluorogenic peptide substrate, t-butyloxycarbonyl-Ile-Glu-Gly-Arg-7-amido-4-methylcoumarin (Boc-IEGR-AMC). The specific activity is >200 pmol/min/µg (QC tested)
- BackgroundCoagulation factor XI is also known as F11, PTA and FXI. Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX. Factor XI is synthesized in the liver and circulates in the plasma as a disulfide bond-linked dimer complexed with high molecular weight kininogen. Selective cleavage of Arg-|-Ala and Arg-|-Val bonds in factor IX to form factor IXa.Factor XI is converted into XIa via either the contact phase of blood coagulation or thrombin-mediated activation on the platelet surface. The resulting XIa converts factor IX into IXa, which subsequently activates factor X into Xa.
- References
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
